Many of today's drug discovery programs utilize high-throughput screening methods that rely on quick evaluations of protein activity to rank potential chemical leads. By monitoring biologically relevant protein-ligand interactions, NMR can provide a means to validate these discovery leads and to optimize the drug discovery process. NMR-based screens typically use a change in chemical shift or linewidth to detect a protein-ligand interaction. However, the relatively low throughput of current NMR screens and their high demand on sample requirements generally makes it impractical to collect complete binding curves to measure the affinity for each compound in a large and diverse chemical library. As a result, NMR ligand screens are typically limited to identifying candidates that bind to a protein and do not give any estimate of the binding affinity. To address this issue, a methodology has been developed to rank binding affinities for ligands based on NMR-based screens that use 1D 1 H NMR line-broadening experiments. This method was demonstrated by using it to estimate the dissociation equilibrium constants for twelve ligands with the protein human serum albumin (HSA). The results were found to give good agreement with previous affinities that have been reported for these same ligands with HSA.
INTRODUCTION
Over the last decade, nuclear magnetic resonance (NMR) spectroscopy has evolved as an important tool for drug discovery. 1 Current NMR screening methods complement structural biology efforts by validating chemical leads from high-throughput screening (HTS) prior to initiating a structure-based drug design program. 2-7 The first NMR screening methods, such as SAR by NMR, 4 RAMPED-UP NMR, 8 and NMR-SOLVE, 9 were developed to identify ligands that bind a therapeutic target in a biologically-relevant manner by observing chemical shift changes in two-dimensional (2D) 1 H-15 N HSQC spectra. However, these methods tend to be resource-intensive. Also, their relatively low throughput makes it impractical to use these methods for collecting complete binding curves that allow binding affinities (often represented by the dissociation equilibrium constant, K D ) to be measured as an integral component of an NMR screen. To overcome these issues, recent methods such as MS/NMR 10 and multi-step NMR screen 11 have applied a tiered approach to screening that joins complementary techniques to increase throughput and minimize resource usage. For instance, the multi-step NMR screen combines one-dimensional (1D) 1 H NMR line-broadening experiments and 2D 1 H- 15 N HSQC chemical shift perturbation experiments to identify drug discovery leads from a biologically-relevant, small-molecule library. 12
Ligand-focused 1D NMR methods are well suited to identify hits from large chemical libraries because they favor weak-affinity ligands (i.e., ligands with K D values in the range of μM-mM), decrease data-collection time, and reduce overall sample requirements. 7 In addition, with the advent of sample changers and flow-probes, ligand-focused 1D NMR experiments can be readily adapted to automation to give a corresponding increase in throughput. 7, 13-17 A number of fast, ligand-focused 1D NMR experiments exist that exploit differences in relaxation rates, diffusion rates, saturation transfers, or NOE transfers to identify protein-ligand complexes. 3, 18 In general, a binding event is identified by using a change in linewidth or chemical shift in the free ligand 1D-1 H NMR spectrum upon the addition of a protein. However, using these measurements to determine the dissociation equilibrium constant for a proteinligand complex as part of an NMR screen is still a challenging task. [19] [20] [21] [22] [23] [24] [25] Similar to traditional measurements, 20 NMR methods rely on the collection of multiple data points to accurately determine a dissociation equilibrium constant or binding affinity for a protein-ligand interaction. 9 This approach is usually impractical in a high-throughput mode that requires a rapid method for characterizing and ranking binding affinities. Examples of single-point K D measurements using 1D NMR experiments have recently been described that use 19 F-containing compounds 21, 22 or the displacement of known low-affinity inhibitors. 24, 26 Unfortunately, these approaches are typically limited in practice because known lowaffinity inhibitors or a large library of "drug-like" and structurally diverse 19 F-containing compounds are not available for a wide range of protein targets.
This report discusses a new NMR screening method that can be used to determine the relative ranking of binding affinities using a variation of traditional 1D 1 H NMR line-broadening experiments. 27, 28 This approach correlates the ratio of NMR peak height for free and bound ligands to the fraction of bound ligand in a protein-ligand complex. This method is illustrated by using human serum albumin (HSA) as a model protein, which is an important secondary target for efficacy screening and a well-established system for monitoring protein-ligand interactions. 29
THEORY
Binding interactions between a large protein (MW > 5000 Da) and a low molecular weight ligand (MW < 500 Da) can be examined by using the decrease in NMR peak height that occurs upon the addition of a protein to a solution with constant ligand concentration. NMR linebroadening experiments follow an opposite protocol from typical experiments that measure K D values, where ligands are added to solutions that contain a constant protein concentration. Thus, a different form for the standard Langmuir binding isotherm is required in the former type of study. If it is assumed that a protein (P) has a 1:1 binding with a ligand (L), the dissociation equilibrium constant for this interaction can be represented by the following equation (1) where [P] F is the concentration of the free protein at equilibrium, [L] F is the corresponding concentration of the free ligand, and [PL] is the concentration of the resulting protein-ligand complex.
Rearrangement of eq 1 produces the following binding isotherm, in which f B represents the "fractional occupancy", or the fraction of bound ligand. (2) It is assumed in many types of binding studies that the total ligand concentration [L] T is approximately equal to the free ligand concentration; however, this assumption is not applicable to the NMR line-broadening experiments used in this study because [L] T is not necessarily in excess of the maximum complex concentration [PL] . Also, a direct measurement of the free protein concentration is not possible for the method described in this report. Therefore, eq 3 was derived to describe this situation in terms of the total protein concentration [P] T and total ligand concentration [L] T that are known to be present in the system (see Appendix for derivation). The fractional occupancy for a protein-ligand complex can be measured using a ratio of NMR peak height (1−I B /I F ), where I B is the sum of ligand NMR peak heights in the presence of the protein and I F is the sum of NMR peak heights for the free ligand. Therefore, B (the NMR peak height ratio) represents an easily measurable response of ligand binding that can be described in terms of the fraction of bound ligand (f B ) and the NMR-linewidth for the free (ν F ) and bound (ν B ) states (see Appendix for derivation). (5) Combining eq 4 and eq 5 leads to a new binding isotherm for this system, as shown below, (6) The unit-less NMR-linewidth ratio constant (c), as defined in eq 6, accounts for the proportional change in ligand linewidth upon binding of a ligand to a protein. Once a ligand is bound, the free ligand linewidth (ν F ) of a ligand resonance adopts the linewidth of the protein (ν B ) and the increase in linewidth produces a corresponding decrease in peak height measured by the ratio of NMR peak height (B).
The dissociation equilibrium constant for a protein-ligand complex that is calculated using eq 6 is based on relative changes in NMR peak height by fitting the given binding isotherm to a complete protein titration curve. This is impractical in the context of an NMR high-throughput screen where only a single titration point is measured. However, eq 6 can be rearranged to solve for K D to yield an estimate for K D that is based on [P] T , [L] T , c and B single , where B single is the fractional occupancy at a single protein concentration. The resulting expression is shown in eq 7. For proteins such as HSA that possess multiple non-specific binding sites, the decrease in ligand signal at a relatively high protein concentration will be an average of specific and nonspecific binding. To correct for this effect, the non-specific binding term n [P] T that corresponds to a linear increase in fraction bound with the addition of protein is simply added to eq 6, as shown in eq 8. 
EXPERIMENTAL SECTION

Materials
The HSA (essentially fatty acid free, ≥ 96% pure), choline bromide (~ 99% pure), clofibrate, furosemide, phenol red, phenylbutazone, phenytoin (~ 99% pure), sodium salicylate, tolbutamide, uridine 5′-monophosphate (98-100% pure) and warfarin (> 98% pure) were purchased from Sigma (St. Louis, MO). The bromophenol blue (ACS reagent grade, 95% pure), bromocresol green (ACS reagent grade, 95% pure), and ibuprofen were from Sigma-Aldrich (Milwaukee, WI). The dimethyl sulfoxide-d 6 (99.9% D), deuterium oxide (99.9 atom% D) and naproxen (98% pure) were obtained from Aldrich (Milwaukee, WI). The 3-(trimethylsilyl) propionic-2,2,3,3-d 4 acid sodium salt (98% D) was purchased from Cambridge Isotope (Andover, MA). The potassium phosphate dibasic salt (anhydrous, 99.1% pure) and monobasic salt (crystal, 99.8% pure) were purchased from Mallinckrodt (Phillipsburg, NJ).
Apparatus
All NMR spectra were collected on a Bruker 500 MHz Avance spectrometer (Billerica, MA) equipped with a triple-resonance, Z-axis gradient cryoprobe and using a Bruker BACS-120 sample changer and IconNMR software for automated data collection. Spectra were collected at 298 K using 512 transients, a sweep-width of 6009 Hz, 16 K data points and a relaxation delay of 2.0 s. The residual HDO resonance signal was suppressed with pre-saturation. The total experiment time, including sample changing for each spectrum, was approximately 33 min.
Sample Preparation
All small-molecule ligands that were used in this study were selected based on their previously reported K D values for HSA and their good solubility in an aqueous solution. 29 The smallmolecule ligand samples were individually prepared in 10 mL stock solutions that contained 20 μM ligand, 1% (v/v) dimethyl sulfoxide-d 6 (DMSO-d 6 ), 10 μM 3-(trimethylsilyl) propionic-2,2,3,3-d 4 acid sodium salt (TSP) and pH 7.0 (uncorrected) 50 mM potassium phosphate buffer prepared in deuterium oxide.
A series of ten HSA stock solutions were prepared in deuterium oxide by making serial dilutions from a 200 μM master solution of HSA in deuterium oxide. The final concentrations of HSA in these stock solutions ranged from 0 μM to 200 μM and were prepared so that a 10 μL addition of the HSA stock solution to 490 μL of a free ligand solution resulted in final concentrations of 0 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM, 2 μM, 3 μM, and 4 μM HSA, respectively. These mixtures were prepared individually for each ligand in 1.5 mL microcentrifuge tubes and then transferred to NMR tubes. The sample for each titration that contained 0 μM HSA was used as the reference for calculating the free ligand intensities (I F ) and free ligand linewidths (ν F ). All binding studies performed with these solutions were conducted at 25°C.
1D 1 H NMR Binding Curves
Spectra were processed with the ACD/1D NMR manager (Advanced Chemistry Development, Inc., Toronto, Ontario). A linear prediction algorithm was applied to the FID in the forward direction and the resulting FID was Fourier transformed. The NMR spectrum was phaseadjusted and baseline-corrected. The residual water signal was removed for clarity using the solvent removal function in ACD. This function simply sets the spectrum's baseline to zero around the residual water signal. All ligand resonance peaks were visually selected and peak positions were measured relative to a TSP reference set to 0.0 ppm. Peak height were measured relative to the DMSO-d 6 peak at 2.69 ppm that was normalized to an height of 1.00. The DMSOd 6 peak was completely recovered during the 1D 1 H NMR experiment using a 2.0 s recycle delay, which is >3x the T1 for DMSO in D2O at 299K (0.3-0.5 s). 30, 31 Individual peak heights in the aromatic region for each ligand were summed to obtain the free (I F ) and bound (I B ) heights at each titration point. The peak-height ratios were plotted versus total protein concentration and fit to eq 8 using the program KaleidaGraph version 3.52 for Windows (Synergy Software., Reading, PA) to estimate the K D value for each protein-ligand complex. The average NMR-linewidth ratio (c) for each ligand was estimated by using eq 6, where ν B was taken to be approximately 94.2 Hz using a previously measured correlation time for HSA of 41 ns. 32 The value for ν F was calculated as described in the next section. The fit of each binding curve was constrained so that K D ≥ 0 in these studies.
Measuring a Free Ligand NMR-linewidth (ν F )
To measure the free ligand linewidth (ν F ) for use in eq 6, the NMR spectrum for each free ligand (i.e., as obtained in a solution containing no HSA) was processed as described above to avoid any distortion in linewidth resulting from processing. NMR peak linewidths were measured using the ACD/1D NMR manager peak fitting routine. The average peak linewidth was used to report ν F for each ligand and to calculate the NMR-linewidth ratio.
Simulated High-Throughput Screening by NMR
To simulate the outcome of an NMR high-throughput screening assay, a single protein concentration [P] T from the full titration curve was used. On average, the 0.2 μM HSA titration point yielded a large response for all 12 ligands without reaching saturation. The static total ligand concentration [L] T was 20 μM. A simulated response curve was generated by fitting a range of K D values to a range of ideal B single values calculated using eq 7. The measured B single value for each ligand at the 0.2 μM HSA titration point was used to calculate a singlepoint binding constant from eq 7 and compared to the simulated response curve. This simulated experiment used both the individual c values calculated for each ligand from the full titration experiment and an average c value calculated from the 12 NMR titration curves. The singlepoint dissociation equilibrium constant for each ligand was calculated using this average c value.
RESULTS AND DISCUSSION
Measuring K D from 1D 1 H NMR Line-Broadening Experiments
The development of NMR-based screening assays that monitor changes in chemical shifts or linewidth as a means to identify or verify initial chemical leads has evolved to become an increasingly important component of drug discovery efforts in the biotechnology and pharmaceutical industry. 33, 34 Nevertheless, the direct measurement of a binding affinity from a high-throughput NMR screen is generally lacking. 21-25 A decrease in the height of a ligand's NMR signal in the presence of a protein is commonly used in NMR-based screens to monitor the formation of a protein-ligand complex. 1D 1 H NMR spectra of small-molecules (MW ≤ 500 Da) usually have extremely sharp peaks due to slow dipole-dipole relaxation (T 2 ). 3 Binding to a high molecular weight agent like a protein induces peak broadening and a corresponding decrease in the ligand's NMR signal height because the bound ligand now experiences the shorter relaxation time of the protein. This effect is illustrated in Figure 1 using binding by the protein HSA to the drugs phenytoin and naproxen as examples.
The observed increase in ligand linewidth in such an experiment will depend on a number of factors that include the dissociation equilibrium constant for the protein-ligand interaction, K D . In general, the observed change in the ligand's linewidth (ν obs ) for the fast exchange limit will follow the result shown below. (9) In eq 9, f B is the fraction of the bound protein-ligand complex, ν F is the free ligand NMRlinewidth, and ν B is the linewidth for the bound state of the ligand (see the Appendix for an explanation regarding the above expression for f B ). Eq 9 shows that an increase in the observed ligand linewidth will be related to the free and bound ligand linewidths and the value of K D for the protein-ligand complex. If it is assumed that the linewidth of the protein-ligand complex is significantly larger than that for the free ligand, the ratio of the ligand linewidth in the presence and absence of the protein should represent the remaining free ligand concentration, as indicated by eq 6. This relationship assumes that there is a lack of any significant contribution of chemical or dynamic exchange to the observed change in linewidth. This is a reasonable assumption in the context of a high-throughput NMR screen against a single protein target. First, initial chemical leads tend to be weak binders in the fast exchange regime, where the linewidth change of the ligand will be dominated by the linewidth of the protein. Second, biologically relevant binders will interact with the same or similar binding sites on the protein. Under these circumstances, the ligand may experience a relatively constant contribution of chemical and dynamical linebroadening. Thus, the minimal contribution of linewidth from exchange processes should not affect the relative ranking of the ligand binding affinities that are obtained when using such an experimental approach.
The validity of this method for high-throughput screening by NMR was examined by using twelve ligands with previously determined binding affinities to HSA. 29, 35-38 These ligands were used to examine the relationship between the estimated values for K D and the relative ratios of the NMR Peak height. Samples containing 20 μM of any given ligand were titrated with solutions that contained 0 to 4 μM of HSA to develop full binding curves for each of the twelve ligands. As a control, two suspected non-binding ligands (i.e., choline bromide and uridine-5′-monophosphate) were also screened in the presence of HSA with no observable decrease in signal (data not shown). The K D values that were obtained by this method (see Table 1 ) were experimentally determined by directly fitting the resulting binding curve of each ligand to eq 8. These fits gave a sum of residuals squared that ranged between 0.977 and 0.998 over the ten concentrations of HSA that were tested. Figure 2 shows the results that were obtained for three of the tested ligands, which have previously reported dissociation equilibrium constants that ranged from 0.7 to 36.8 μM. These figures and the corresponding fits illustrate the ability of this approach to be used with ligands that have weak-to-moderate strength binding to proteins such as HSA.
Co-variance of K D and the NMR-linewidth Ratio (c)
Ideally, the dissociation equilibrium constant (K D ) and the NMR-linewidth ratio (c) could be simultaneously derived by fitting eq 6 to the experimental NMR binding curves. Unfortunately, K D and c are completely covariant. This requires an approximation for c in order to calculate K D from the NMR binding curves. The linewidth of a protein (ν P ) may provide a lower estimate of ν B if it is assumed that ν B is dominated by the protein linewidth (ν P ). Estimations of ν P can be made from the correlation time (τ c ) of the protein by using the intramolecular dipole-dipole relaxation rate constant (T 2 −1 ). 39 (10) where (11) In these equations, J(ω) is the normalized spectral density function, μ o is the vacuum permeability, γ is the magnetogyric ratio, ω is frequency (rad s −1 ), ħ is Plank's Constant, B 0 is the static magnetic field strength and r is the hydrodynamic radius of the protein. In addition, the Stokes-Einstein equation can be used to relate τ c to the molecular weight (MW) for a globular protein, 40 (12) where T is the temperature, k is the Boltzmann constant, η is the viscosity of the solvent, r is the radius and ρ is the shape constant.
The reliability of eq 12 to approximate a protein correlation time from its molecular weight is illustrated from a comparison between 27 experimental τ c values 41, 42 and correlation times predicted using eq 12 ( figure 3A) . A linear best-fit was obtained with an R 2 of 0.81 in this case.
For a high-throughput screen, ν p can be estimated from the molecular weight of a protein by using this approximation for τ c with a shape constant of 1.32 combined with eq 10 and 11. The shape constant was determined by optimizing a linear fit between the experimental and predicted τ c values shown in Figure 3A by varying ρ. The result is an approximate correlation between ν P and MW P , as shown in eq 13.
This dependency of linewidth on the size and shape of a protein is plotted in Figure 3B . For HSA (MW, 66 kDa), the correlation time (41 ns) has previously been measured using timeresolved fluorescence. 32 This correlation time was used to calculate the value used for ν P , which was 94.2 Hz.
The free ligand linewidth (ν F ) can be measured directly from the NMR spectra of the free ligand using an average ligand linewidth. Average ν F values measured from the free ligand NMR spectra are reported in Table 1 . However, for large and diverse chemical libraries it may not be feasible to measure an accurate linewidth for each compound. Alternatively, ν F is generally between 1 and 2 Hz for many small-molecules (MW, 500 < Da), which provides a reasonable estimate for ν F to calculate an average value for c.
Sensitivity of K D and NMR-linewidth Ratio (c)
A closer examination of eq 6 indicates that the NMR-linewidth ratio (c) acts as a scaling factor in the calculation of K D , with a larger c value resulting in a proportionally larger K D value. Unfortunately, small variations or errors in the measurement of ν F will result in proportionally larger variations in both c and K D . In the context of high-throughput screening by NMR, an incorrect estimate of c will result in a systematic underestimation or overestimation of K D . However, the relative ranking of the ligand binding affinities will be maintained. In addition, a lower limit to c is inherently defined by eq 6. Table 1 (for both the NMR and literature results) should be regarded as weighted averages and as measures of the global affinity for a particular ligand with HSA. This averaging effect may be more pronounced for the NMR method than for other techniques because of the practical limit in ligand concentration that could be used to provide a measurable signal. There is also a practical limit to the number of concentrations and data points that could be sampled to give a binding curve. This effect may explain why the NMR-derived K D values tend to be lower than the literature values, because the use of higher concentrations for the NMR studies would give a higher weight and likelihood to the detection of weaker interactions between the ligand and protein.
Comparison of Estimated K D Values with Literature Values
A number of other practical limitations also need to be considered in the use of NMR for these binding studies. For instance, the NMR resonances that are specifically involved with protein binding have been shown to exhibit the most dramatic changes in linewidth. 27, 28 Therefore, there are inherent errors caused by summing all peak height and selectively excluding ligand peaks due to an overlap with buffer and protein resonances. In addition, errors in the measurement of peak height might arise at lower ligand concentrations due to the difficulty of accurately identifying and selecting peaks under these conditions. The result could be either a low or high estimate for K D , depending on the disparity in linewidth changes and on which peaks are excluded. Using overlapping peaks would introduce an alternative error because the observed height is the sum of multiple peaks that cannot be easily de-convoluted. Also, the analysis of hundreds to thousands of NMR spectra in a high-throughput screening assay precludes a manual inspection to selectively determine which peaks to include or exclude.
Estimating K D based on Single-point 1D 1 H NMR Line-Broadening Measurements
Since NMR-based screens are a common component of the drug discovery process in the pharmaceutical industry, single-point estimates of ligand binding affinities could be an extremely valuable tool to initially rank and prioritize chemical leads. During the iterative drug optimization process, it is typical to focus on a small set (i.e., 3-5 compounds) of structurally distinct chemical classes that are amenable to synthetic modification and that exhibit drug-like characteristics. 68 For this work, an NMR screen could be used to verify the presence of a specific and biologically-relevant interaction involving a protein target and to rank the relative binding affinity of the screened ligands to simplify the selection of promising lead compounds. This approach was illustrated in this study by simulating NMR high-throughput screening results for the twelve compounds that were used in the previous binding study.
First, using an average c value of 45.7 ±11.6 and an HSA concentration of 0.2 μM, single point K D values were calculated for a range of B single values using eq 7. The result of this calculation are shown in Figure 4 . Superimposed on the single point curve in Figure 4A are the K D values reported in Table 1 plotted versus the experimental B values at 0.2 μM HSA. Superimposed on the single point curve in Figure 4B are the K D values from Table 1 , where the corresponding c values were used to determine a best-fit to eq 8. This represents the typical protocol that would be used in a high-throughput screen and shows that an average value of c is acceptable for use when individual estimates of c may not be practical. A comparison of Figure 4B with the theoretical curve based on eq 7 indicates that the single-point method can provide a reasonable approximation for K D.
For the twelve compounds that were considered in Figure 4B , all compounds gave single-point estimates that agreed within a range of one standard deviation over the range of binding affinities and concentrations that were tested. All twelve compounds had experimental and single-point estimates for K D that agreed within two standard deviations. A higher deviation was observed in Figure 4A for ligands with higher K D values. This occurs because of differences between the individual c values and the average c values. Also, eq 8 is more sensitive to small changes in c at these high K D values. This occurs because, at high K D values, vanishingly small differences in NMR intensities correspond to large differences in K D . In other words, this method is reaching a practical limit of detection since K D rapidly approaches infinity as NMR peak height changes approach zero.
The relative ranking of the K D values were also the same for results that were obtained by the single-point calculations or the full titration method. These results indicate that the single-point method can, at least in cases such as these, provide a preliminary estimate of K D values and binding affinities that can be used in the context of a high-throughput screening assay. At a minimum, the relative changes in linewidth provide a rapid and efficient mechanism to prioritize NMR screening leads for further evaluation. However, it is still recommended that a more robust approach for measuring binding affinities for promising leads follow the NMR ligand affinity screen. This precaution follows, in part, from the fact that the accuracy of the K D values that are measured from the single-point 1 H NMR line-broadening experiments will be strongly dependent on having a reasonable estimate for the value of NMR-linewidth ratio (c) in such a study. 
CONCLUSIONS
which makes it possible to solve for [P] F by using the quadratic formula, as indicated in eq A6, where only the positive root has any meaning in a real protein-ligand system.
The bound fraction of ligand f B is next defined as given in eq A7.
(A7)
If we substitute the positive root of eq A6 into eq A7, the result is eq A8. If eq A9 is truncated at the second term, this allows the square root term in eq A8 to be written in the approximate form that is given in eq A10.
The overall result of this simplification is that eq A8 converts to the expression shown below, there the fraction of bound ligand f B is now described in terms of only K D , the total ligand concentration and the total protein concentration.
If it is assumed that the observed free and bound NMR-linewidths are represented by ν F and ν B , respectively, and that exchange occurs between free and bound states, the general solution to the NMR lineshape is bilorentzian. In the slow limit, the spectrum is obviously just a sum of the spectra of free and bound species, weighted by their relative abundances. If exchange rates become comparable to the inverse linewidths, then a conventional solution of the pair of coupled linear differential equations, including auto and cross relaxation terms but neglecting any chemical shift difference between the states, gives a time domain (free induction decay):
where M L and M PL are the magnetization of the free and bound species, respectively. In the fast exchange limit, the solution is still formally biexponential, but the coefficient c-goes to zero, and the free induction decay signal, normalized to unity at zero time, becomes
Fourier transforming, the fast exchange NMR signal height can be written as shown in eq A14:
where I F is the height of the ligand signal in the absence of protein and I B is the observed peak height of the bound complex. This is exactly the same as the height of the free ligand signal in extreme slow exchange! Rearranging eq A14 explains the observed decrease in NMR peak signal for a free small-molecule ligand upon its binding to a protein. The relative ratio of NMR peak height ( ) is now in terms of the fraction of free ligand (f F ) and the fraction of bound ligand (f B ) and is dependent on the observed increase in NMR-linewidth upon the binding of a ligand to a protein.
(A15)
Inserting A11 into A15 provides a measure of the dissociation equilibrium constant for the protein-ligand complex by relating the fraction of bound ligand to the observed change in NMR peak height.
The NMR-linewidth ratio, c, is then measured by using the free ligand NMR spectrum and by assuming that the linewidth of the bound complex approximates the linewidth of the protein. Experimental fractional occupancy (B) for naproxen (•), tolbutamide (▲), and phenol red (◆) versus the total concentration of HSA. The best-fit lines were obtained using eq 8. The r 2 for these best-fit lines are given in the text and the K D values that were obtained from these lines are provided in Table 1 . 
